Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Amphastar’s Forteo ANDA Hit With CRL As Wait Goes On
Forteo Has No Tangible Patent Protection But Complexity A Major Hurdle
Jun 14 2022
•
By
Dean Rudge
Amphastar is now likely looking at 2023 • Source: Shutterstock
(Kurt Brady / Alamy Stock Photo/Alamy Stock Photo)
More from Generics
More from Products
